Patents by Inventor Scott Sherrill
Scott Sherrill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11641842Abstract: The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.Type: GrantFiled: June 9, 2021Date of Patent: May 9, 2023Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.Inventors: Ebenezer Satyaraj, Peichuan Sun, Scott Sherrill, Qinghong Li, Steven Hannah
-
Publication number: 20210289739Abstract: The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.Type: ApplicationFiled: June 9, 2021Publication date: September 23, 2021Inventors: Ebenezer Satyaraj, Peichuan Sun, Scott Sherrill, Qinghong Li, Steven Hannah
-
Patent number: 11102952Abstract: The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.Type: GrantFiled: May 21, 2018Date of Patent: August 31, 2021Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.Inventors: Ebenezer Satyaraj, Peichuan Sun, Scott Sherrill, Qinghong Li, Steven Hannah
-
Patent number: 10889785Abstract: Formulations, compositions and products for reducing allergenic Fel d 1 from the environment are disclosed. The formulations include at least one protease that interacts with the Fel d 1 and substantially degrades allergenic epitopes on the Fel d 1. Methods of using the formulations for reducing or eliminating allergenic Fel d 1 from the environment are also disclosed.Type: GrantFiled: April 4, 2018Date of Patent: January 12, 2021Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.Inventors: George Wells, Delphine Tissot-Favre, Ebenezer Satyaraj, Juergen Eck, Daniel Meyer, Torsten Ertongur-Fauth, Alexander Pelzer, Scott Sherrill, Peichuan Sun
-
Patent number: 10731227Abstract: Provided herein include compositions comprising a primer having the nucleic acid sequence of ACeIN-F3_c, a primer having the nucleic acid sequence of ACeIN-B3_a, a primer having the nucleic acid sequence of ACeIN-B3_b, a primer having the nucleic acid sequence of ACeIN-FIP_e, a primer having the nucleic acid sequence of ACeIN-FIP_f, a primer having the nucleic acid sequence of ACeIN-BIP (or ACeIN-BIP-song), a primer having the nucleic acid sequence of ACeIN-LF; and a primer having the nucleic acid sequence of ACeIN-LB. Also provided are methods of detecting human immunodeficiency virus (HIV) nucleic acids in a sample comprising performing reverse transcription-based loop mediated isothermal amplification (RT-LAMP) on a sample using the previously disclosed compositions.Type: GrantFiled: December 11, 2015Date of Patent: August 4, 2020Assignee: The Trustees of the University of PennsylvaniaInventors: Changchun Liu, Scott Sherrill-Mix, Haim H. Bau, Frederic D. Bushman, Karen E. Ocwieja, Jinzhao Song
-
Publication number: 20180338467Abstract: The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.Type: ApplicationFiled: May 21, 2018Publication date: November 29, 2018Inventors: Ebenezer Satyaraj, Peichuan Sun, Scott Sherrill, Qinghong Li, Steven Hannah
-
Publication number: 20180223223Abstract: Formulations, compositions and products for reducing allergenic Fel d 1 from the environment are disclosed. The formulations include at least one protease that interacts with the Fel d 1 and substantially degrades allergenic epitopes on the Fel d 1. Methods of using the formulations for reducing or eliminating allergenic Fel d 1 from the environment are also disclosed.Type: ApplicationFiled: April 4, 2018Publication date: August 9, 2018Inventors: George Wells, Delphine Tissot-Favre, Ebenezer Satyaraj, Juergen Eck, Daniel Meyer, Torsten Ertongur-Fauth, Alexander Pelzer, Scott Sherrill, Peichuan Sun
-
Patent number: 9322832Abstract: The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals.Type: GrantFiled: May 8, 2012Date of Patent: April 26, 2016Assignee: Nestec S.A.Inventors: Steven Scott Hannah, Scott Sherrill, Qinghong Li, Peichuan Sun
-
Publication number: 20150175940Abstract: Formulations, compositions and products for reducing allergenic Fel d 1 from the environment are disclosed. The formulations include at least one protease that interacts with the Fel d 1 and substantially degrades allergenic epitopes on the Fel d 1. Methods of using the formulations for reducing or eliminating allergenic Fel d 1 from the environment are also disclosed.Type: ApplicationFiled: December 15, 2014Publication date: June 25, 2015Inventors: George Wells, Delphine Tissot-Favre, Ebenezer Satyaraj, Juergen Eck, Daniel Meyer, Torsten Ertongur-Fauth, Alexander Pelzer, Scott Sherrill, Peichuan Sun
-
Publication number: 20140147865Abstract: The invention provides methods for diagnosing degenerative joint disease in an animal by collecting a saliva sample from an animal; determining the amount of at least one diagnostic agent selected from the group consisting of interferon gamma, interferoninducible protein-10, interleukin-2, and total saliva protein in the saliva sample; comparing the amount of diagnostic agent found in the saliva sample to a corresponding amount of the same diagnostic agent found in a saliva sample from one or more comparable control animals that do not suffer from degenerative joint disease; and diagnosing that the animal is susceptible to or suffering from degenerative joint disease if the amount of diagnostic agent in the saliva sample from the animal is greater than the amount of same diagnostic agent found in the saliva sample from the one or more comparable control animals.Type: ApplicationFiled: May 8, 2012Publication date: May 29, 2014Applicant: NESTEC SAInventors: Steven Scott Hannah, Scott Sherrill, Qinghong Li, Peichuan Sun
-
Publication number: 20140107218Abstract: The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in animals by administering to the animals an ophthalmic malady ameliorating amount of one or more polyamines. Generally, the polyamines are administered to the animals in amounts of from about 1 to about 200 mg/kg/day to ameliorate maladies such as cataracts and cloudy eye.Type: ApplicationFiled: October 14, 2013Publication date: April 17, 2014Applicant: NESTEC SAInventors: Scott Sherrill, Wei Wang
-
Publication number: 20060270041Abstract: The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).Type: ApplicationFiled: December 12, 2005Publication date: November 30, 2006Inventors: John Howe, Ken Wills, Robert Ralston, Scott Sherrill